Stockley's Drug Interactions

Stockley's Drug InteractionsStockleys Drug Interactions, edited by Claire L Preston, remains the worlds most comprehensive and authoritative international reference book on drug interactions. Based upon thousands of published papers and reports this eleventh edition: Covers interactions between therapeutic drugs, proprietary medicines, herbal medicines, foods, drinks, and drugs of abuse Contains in depth yet concise monographs in an easy to read format Provides comprehensive

Stockley’s Drug Interactions, edited by Claire L Preston, remains the world’s most comprehensive and authoritative international reference book on drug interactions. Based upon thousands of published papers and reports this eleventh edition:

• Covers interactions between therapeutic drugs, proprietary medicines, herbal medicines, foods, drinks, and drugs of abuse
• Contains in-depth yet concise monographs in an easy-to-read format
• Provides comprehensive details of the clinical evidence for the interactions under discussion, an assessment of their clinical importance, and clear guidance on managing the interaction in practice
• Has a brief summary of the interaction in each monograph – perfect for the busy healthcare professional
• Is fully referenced throughout
• Contains almost 4500 monographs
• Is global in coverage – inclusion of drugs used worldwide

New in the 11th edition: 

• Over 350 new monographs added
• Many existing monographs have been reviewed, revalidated, and updated
• A comprehensive update and restructure of the chapter on Antidiabetic drugs, in-line with published literature
• Addition of new advice regarding the concurrent use of aliskiren, ACE inhibitors, and angiotensin-II receptor antagonists
• An updated list of drugs that have a risk of prolonging the QT interval
• The addition of new drugs, including apixaban, apremilast, dolutegravir, lomitapide, mirabegron, the NS5A inhibitors (daclatasvir, ledipasvir, ombitasvir), the NS5B inhibitors (dasabuvir, sofosbuvir), the sodium-glucose co-transporter-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), and telavancin